Could adding a second diabetes drug early save lives?

NCT ID NCT07566299

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study analyzed health records of over 118,000 adults with obesity, type 2 diabetes, and related heart, kidney, and liver conditions. Researchers compared people who added a second type of diabetes drug (GLP-1 or SGLT2) early to those who did not. The goal was to see if early combination therapy reduces death risk over five years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
GLP-1 receptor agonist and SGLT2 inhibitor
What this could lead to
If successful, this could show that adding a second diabetes drug early improves survival and reduces heart, kidney, and liver problems in people with obesity and type 2 diabetes.
What could go wrong
This is an observational study using existing health records, not a controlled trial. Results may be affected by unmeasured factors, and the findings need confirmation in prospective studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARDIOVASCULAR-KIDNEY-METABOLIC SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chung Shan Medical University Hospital

    Taichung, Taichung, 402, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.